Stereotaxis Announces CFO Transition

Announces CFO Transition

LOUIS, MO, Sept. 16, 2019 - Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies

for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer,

effective October 1, 2019. Martin Stammer, who has served as Chief Financial Officer since 2013, has accepted a position as the

CFO of a large professional services firm headquartered in the St. Louis area and will resign from the Company, effective September

have really enjoyed my time at Stereotaxis and firmly believe in the future of the Company," said Martin Stammer. "I

have the utmost confidence in Kim and her team and look forward to seeing them achieve many additional milestones."

Peery joined Stereotaxis in 2003 and currently serves as Vice President of Finance. Prior to Stereotaxis, she served as a controller

at various private companies. Ms. Peery is a Certified Public Accountant and earned a Bachelor of Science in Accounting and Master

of Science in Accounting and Computer Science from Southern Illinois University, Edwardsville. She commented, "I appreciate

the confidence placed in me by the Stereotaxis Board of Directors and look forward to becoming CFO in this exciting period for

Fischel, Chairman and CEO of Stereotaxis, commented, "I appreciate Marty's contributions to Stereotaxis over many

years and wish him well in his future endeavors. He leaves us in a strong position following our recently completed financing

and uplisting to the NYSE American. I am excited to work with Kim and congratulate her on her new leadership role."

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular

procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions

for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and

safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' robotic

technology has received various regulatory clearances in the United States, European Union, Japan, Canada, China, and elsewhere.

The Stereotaxis Genesis RMN System is CE marked and will become available in other global geographies subject to regulatory approvals.

Stereotaxis Imaging Model S is CE marked and FDA cleared. For more information, please visit www.stereotaxis.com.

press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe",

"estimate", "project", "expect" or similar expressions. Forward-looking statements inherently

involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors

that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional

capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable

levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing,

in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic

conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors,

changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence

upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings

with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation

to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company

will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of

these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition,

these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations,

or by overall project changes or delays.

and Chief Executive Officer